Serum MicroRNA Expression Profile: MiR-1246 As a Novel Diagnostic and Prognostic Biomarker for Oesophageal Squamous Cell Carcinoma

Overview

Journal Br J Cancer

Specialty Oncology

Date 2013 Jan 31

PMID 23361059

Citations 148

Authors

N Takeshita

I Hoshino

M Mori

Y Akutsu

N Hanari

Y Yoneyama

N Ikeda

Y Isozaki

T Maruyama

N Akanuma

A Komatsu

M Jitsukawa

H Matsubara

Affiliations

Soon will be listed here.

Abstract

Background: Recent studies have demonstrated that microRNAs (miRNAs) are stably detectable in blood and can serve as useful biomarkers for cancer.

Methods: We performed an miRNA array using serum samples obtained from oesophageal squamous cell carcinoma (ESCC) patients or healthy controls. MiR-1246 was the most markedly elevated in ESCC patients. Therefore, miR-1246 was selected as a candidate for further analysis. The serum miR-1246 level in 46 healthy controls and 101 ESCC patients was evaluated and compared among various clinicopathological characteristics. MiR-1246 expressions in tissue, exosomal, and cellular samples were also examined.

Results: Serum miR-1246 alone yielded an receiver-operating characteristic curve area of 0.754, with 71.3% sensitivity and 73.9% specificity for distinguishing ESCC patients from healthy controls. Serum miR-1246 was significantly correlated with the TNM stage and showed to be the strongest independent risk factor for poor survival (HR, 4.032; P=0.017). Unlike the tendency shown in previous reports, miR-1246 was not upregulated in ESCC tissue samples. Furthermore, exosomal miR-1246 did not reflect the abundance in the cell of origin.

Conclusion: These data support our contention that serum miR-1246 has strong potential as a novel diagnostic and prognostic biomarker in ESCC, and its releasing mechanism is selective and independent of tissue miRNA abundance.

Citing Articles

Circulating exosome-derived miR-191-5p is a novel therapeutic biomarker for radiotherapy in esophageal squamous cell carcinoma patients.

Wang H, Matsumoto Y, Maiyulan A, Toyozumi T, Otsuka R, Sekino N Esophagus. 2025; .

PMID: 40064799 DOI: 10.1007/s10388-025-01116-9.

Extracellular vesicles as a promising biomarker resource in liquid biopsy for cancer.

Tamura T, Yoshioka Y, Sakamoto S, Ichikawa T, Ochiya T Extracell Vesicles Circ Nucl Acids. 2024; 2(2):148-174.

PMID: 39703905 PMC: 11656527. DOI: 10.20517/evcna.2021.06.

Exosomes in esophageal cancer: function and therapeutic prospects.

Wang C, Shi Z Med Oncol. 2024; 42(1):18.

PMID: 39601925 DOI: 10.1007/s12032-024-02543-x.

Extracellular vesicles from highly invasive melanoma subpopulations increase the invasive capacity of less invasive melanoma cells through mir-1246-mediated inhibition of CCNG2.

Kingreen T, Kewitz-Hempel S, Rohde C, Hause G, Sunderkotter C, Gerloff D Cell Commun Signal. 2024; 22(1):442.

PMID: 39285403 PMC: 11403849. DOI: 10.1186/s12964-024-01820-6.

A study of microRNAs as new prognostic biomarkers in anal cancer patients.

Dahl O, Myklebust M Acta Oncol. 2024; 63:456-465.

PMID: 38899393 PMC: 11332526. DOI: 10.2340/1651-226X.2024.27976.

References

Heneghan H, Miller N, Lowery A, Sweeney K, Newell J, Kerin M . Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010; 251(3):499-505. DOI: 10.1097/SLA.0b013e3181cc939f. View

Chim S, Shing T, Hung E, Leung T, Lau T, Chiu R . Detection and characterization of placental microRNAs in maternal plasma. Clin Chem. 2008; 54(3):482-90. DOI: 10.1373/clinchem.2007.097972. View

Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z . Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A. 2009; 106(11):4402-7. PMC: 2657429. DOI: 10.1073/pnas.0813371106. View

Lawrie C, Gal S, Dunlop H, Pushkaran B, Liggins A, Pulford K . Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008; 141(5):672-5. DOI: 10.1111/j.1365-2141.2008.07077.x. View

Ng E, Chong W, Jin H, Lam E, Shin V, Yu J . Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009; 58(10):1375-81. DOI: 10.1136/gut.2008.167817. View

Mroczko B, Kozlowski M, Groblewska M, Lukaszewicz M, Niklinski J, Jelski W . The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients. Clin Chim Acta. 2007; 389(1-2):61-6. DOI: 10.1016/j.cca.2007.11.023. View

Hunter M, Ismail N, Zhang X, Aguda B, Lee E, Yu L . Detection of microRNA expression in human peripheral blood microvesicles. PLoS One. 2008; 3(11):e3694. PMC: 2577891. DOI: 10.1371/journal.pone.0003694. View

Wong T, Liu X, Wong B, Ng R, Yuen A, Wei W . Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin Cancer Res. 2008; 14(9):2588-92. DOI: 10.1158/1078-0432.CCR-07-0666. View

Barber T, Duong C, Leong T, Bressel M, Drummond E, Hicks R . 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data. J Nucl Med. 2012; 53(6):864-71. DOI: 10.2967/jnumed.111.101568. View

10.

Cheng Y, Tan N, Yang J, Liu X, Cao X, He P . A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin Sci (Lond). 2010; 119(2):87-95. PMC: 3593815. DOI: 10.1042/CS20090645. View

11.

Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y, Iwai N . Plasma miR-208 as a biomarker of myocardial injury. Clin Chem. 2009; 55(11):1944-9. DOI: 10.1373/clinchem.2009.125310. View

12.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

13.

Terashima M, Ikeda K, Ishida K, Saito K . Establishment of an esophageal squamous cell carcinoma tumor line and development of serum squamous cell carcinoma-related antigen in athymic nude mice. J Surg Oncol. 1990; 44(4):225-8. DOI: 10.1002/jso.2930440407. View

14.

Calin G, Trapasso F, Shimizu M, Dumitru C, Yendamuri S, Godwin A . Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med. 2005; 352(16):1667-76. DOI: 10.1056/NEJMoa042280. View

15.

Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N . Serum microRNAs are promising novel biomarkers. PLoS One. 2008; 3(9):e3148. PMC: 2519789. DOI: 10.1371/journal.pone.0003148. View

16.

Schickel R, Boyerinas B, Park S, Peter M . MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 2008; 27(45):5959-74. DOI: 10.1038/onc.2008.274. View

17.

Iguchi H, Kosaka N, Ochiya T . Secretory microRNAs as a versatile communication tool. Commun Integr Biol. 2010; 3(5):478-81. PMC: 2974086. DOI: 10.4161/cib.3.5.12693. View

18.

Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X . Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2009; 127(1):118-26. DOI: 10.1002/ijc.25007. View

19.

Resnick K, Alder H, Hagan J, Richardson D, Croce C, Cohn D . The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2008; 112(1):55-9. DOI: 10.1016/j.ygyno.2008.08.036. View

20.

Liu H, Zhu L, Liu B, Yang L, Meng X, Zhang W . Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett. 2011; 316(2):196-203. DOI: 10.1016/j.canlet.2011.10.034. View